Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma

Next Previous
Trial Profile

A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 18 Sep 2025 According to a K36 Therapeutics media release, translational data from this trial will be presented at the 22nd Annual International Myeloma Society (IMS) Meeting in Toronto, taking place September 17-20.
  • 16 Sep 2025 According to a K36 Therapeutics media release, initial patients dosed in multiple cohorts of the phase 1 dose-expansion study assessing KTX-1001 in combination with standard of care and mezigdomide for multiple myeloma. Also, company has begun dosing patients in a separate cohort evaluating KTX-1001 in combination with mezigdomide. The dose expansion cohorts are open in the U.S. and EU.
  • 10 Jul 2025 Protocol amended to include combination drug arms.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top